Modern Pediatrics. Ukraine. (2026).2(154): 35-39. doi: 10.15574/SP.2026.2(154).3539
Khapchenkova D. S.¹, Ivanova V. G.^2
1Donetsk National Medical University, Kropyvnytsyi, Ukraine
²MNCE «Regional Children's Clinical Hospital'»of the Kirovohrad Regional Council, Kropyvnytskyi, Ukraine

For citation: Khapchenkova DS, Ivanova VG. (2026). New perspectives on the use of the medicinal product «Cardonate» in pediatric practice. Modern Pediatrics. Ukraine. 2(154): 35-39. doi: 10.15574/SP.2026.2(154).3539.
Article received: Jan 25, 2026. Accepted for publication: Mar 16, 2026.

All forms of juvenile idiopathic arthritis (JIA) are associated with a decrease in health-related quality of life and with the risk of chronic joint damage. At the same time, the disease may persist even after reaching adulthood. Considering the prevalence of JIA among the pediatric population, the need for prolonged pathogenetic treatment in this group of patients raises the issue of enhancing the natural adaptive capacities of the body, reducing the negative effects of immunosuppressive therapy by adding supplements to the diet to improve the health status of this cohort of children.
Aim – to determine the effectiveness of the medicinal product «Сardonatе» in children with JIA against the background of immunosuppressive therapy.
Materials and methods. Against the background of basic therapy, 30 children with JIA received the medicinal product «Cardonate». The effectiveness of the combined therapy was assessed based on clinical indicators, laboratory and instrumental data before and after taking.
Results. Against the background of taking the medicinal product «Cardonate», patients experienced an improvement in well-being, a decrease in transaminase levels was noted, and an improvement in electrocardiographic indicators was observed.
Conclusions. The medicinal product «Cardonate» can be used in the complex therapy of children with JIA to reduce the manifestations of metabolic dysfunction against the background of immunosuppressive therapy.
The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patients was obtained for conducting the studies.
No conflict of interest was declared by the author.
Keywords: children, the medicinal product «Cardonate», transaminases, juvenile idiopathic arthritis.

REFERENCES

1. Boyko Ya. (2019). Juvenile idiopathic arthritis. Lviv: Svit.

2. Helton E, Darragh R, Francis P et al. (2015). Metabolic aspects of myocardial disease and a role for L-carnitine in the treatment of childhood cardiomyopathy. Pediatrics. 125: 1260-1270. https://doi.org/10.1542/peds.105.6.1260; PMid:10835067

3. Leitão AMF, Silva BR, Barbalho EC, Paulino LRM, Costa FDC et al. (2024, Oct). The role of L-carnitine in the control of oxidative stress and lipid β-oxidation during in vitro follicle growth, oocyte maturation, embryonic development and cryopreservation: a review. Zygote. 32(5): 335-340. Epub 2024 Nov 7. https://doi.org/10.1017/S096719942400039X; PMid:39506889

4. Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST et al. (2022, Apr). 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 74(4): 521-537. Epub 2022 Mar 1. https://doi.org/10.1002/acr.24853; PMid:35233986 PMCid:PMC10124899

5. Pekala J, Patkowska-Sokoła B, Bodkowski R, Jamroz D, Nowakowski P et al. (2011, Sep). L-carnitine – metabolic functions and meaning in humans life. Curr Drug Metab. 12(7): 667-678. https://doi.org/10.2174/138920011796504536; PMid:21561431

6. Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA. Becker ML et al. (2019). 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 71: 846-863. https://doi.org/10.1002/art.40884; PMid:31021537 PMCid:PMC6561114

7. Rutjes AWS, Denton DA, Di Nisio M, Chong LY, Abraham RP, Al‐Assaf AS et al. (2018). Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. Cochrane Database of Systematic Reviews. 12: CD011906. https://doi.org/10.1002/14651858.CD011906.pub2; PMid:30556597 PMCid:PMC6353240

8. Sorokman TV, Lozyuk IYa. (2021). Eating behavior and nutrition characteristics of preschool children. Modern Pediatrics. Ukraine. 5(117): 29-34. https://doi.org/10.15574/SP.2021.117.29

9. Thomas R, Siliquini, R, Hillegers MH, Jansen PW. (2020). The association of adverse life events with children's emotional overeating and restrained eating in a population based cohort. The International journal of eating disorders. 53(10): 1709-1718. https://doi.org/10.1002/eat.23351; PMid:32702148 PMCid:PMC7589411

10. Vlasenko MV, Palamarchuk AV, Golovan AV. (2022). Use of Neurovitan in the Treatment of Endocrine Polyneuropathy. Іnternational journal of endocrinology (Ukraine). 3(59): 73-74. https://doi.org/10.22141/2224-0721.3.59.2014.76608

11. Wang Z-Y, Liu Y-Y, Liu G-H, Lu H-B, Mao C-Y. (2018). L-Carnitine and heart disease. Life Sciences. 194: 88-97. https://doi.org/10.1016/j.lfs.2017.12.015; PMid:29241711